Consumer health and hygiene giant Reckitt Benckiser’s (RKT) Q4 like-for-like sales beat expectations as the Durex seller benefited from strong emerging markets growth. The Slough-based group also provided a confident outlook, guiding for FY26 ‘Core Reckitt’ like-for-like revenue growth within its 4% to 5% medium-term range. So why did the shares slide 4% to £58.23 … Continue reading Reckitt Benckiser beats Q4 sales estimates